Novo Nordisk at ACC 2025: Ozempic® with Once Weekly Semaglutide 1mg Shown to Improve Walking Distance and Quality of Life in Adults with Type 2 Diabetes and Peripheral Artery Disease

Novo Nordisk in the NEWS

Novo Nordisk (NVO) presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.